Stem cell biotech of the year 2012: Advanced Cell Technology (ACTC)
For the second year in a row (see awards 2011), Advanced Cell Technology (ACT; stock symbol ACTC) is my stem cell biotech of the year. Their trials for different forms of macular degeneration (here and here and here) are progressing well and as a stem cell scientist I really appreciate the fact they are publishing their […]
Stem cell biotech of the year 2012: Advanced Cell Technology (ACTC) Read More »